Kezar Life Sciences, Inc.

NASDAQ:KZR

7.37 (USD) • At close November 8, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019201820172016
Revenue 70000000
Cost of Revenue 1.0661.0231.511.5441.3010.690.1750.154
Gross Profit 5.934-1.023-1.51-1.544-1.301-0.69-0.175-0.154
Gross Profit Ratio 0.8480000000
Reseach & Development Expenses 85.69751.00938.93530.98127.36318.1366.4697.373
General & Administrative Expenses 26.5420.15315.72411.9699.9796.592.281.617
Selling & Marketing Expenses -1.0660000000
SG&A 25.47420.15315.72411.9699.9796.592.281.617
Other Expenses 6.1870000000
Operating Expenses 111.17171.16254.65942.9537.34224.7268.7498.99
Operating Income -105.237-71.162-54.659-42.95-37.342-24.726-8.749-8.99
Operating Income Ratio -15.0340000000
Total Other Income Expenses Net 3.3672.9230.0291.2082.2551.5590.2320
Income Before Tax -101.87-68.239-54.63-41.742-35.087-23.167-8.517-8.99
Income Before Tax Ratio -14.5530000000
Income Tax Expense 0.898-2.923-1.351-2.752-3.5561.55900
Net Income -101.87-65.316-53.279-38.99-31.531-23.167-8.517-8.99
Net Income Ratio -14.5530000000
EPS -1.4-0.97-1.01-0.89-1.65-2.26-0.65-0.69
EPS Diluted -1.4-0.97-1.01-0.89-1.65-2.26-0.65-0.69
EBITDA -104.171-71.162-54.471-42.95-37.342-24.726-8.574-8.836
EBITDA Ratio -14.8820000000